Pfiz­er’s alope­cia tablet ap­proved by FDA in adults and teens, win­ning broad­er mar­ket than Lil­ly's Olu­mi­ant

The FDA has giv­en a thumbs-up to the first treat­ment op­tion for ado­les­cents with alope­cia area­ta, an au­toim­mune dis­ease that leads to hair loss.

The agency last Fri­day ap­proved Pfiz­er’s Lit­fu­lo for peo­ple 12 years and old­er, and reg­u­la­to­ry de­ci­sions are ex­pect­ed in the EU, UK, Cana­da and Japan lat­er this year, a spokesper­son said. The drug, known in­ves­ti­ga­tion­al­ly as ritlecitinib, is al­so in Phase III test­ing for vi­tili­go and in mid-stage stud­ies for ul­cer­a­tive col­i­tis and Crohn’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER